Initiation and interruption in intravenous bisphosphonate therapy among patients with multiple myeloma in the United States.

Challenge

IV bisphosphonate therapy for multiple myeloma patients is associated with significant clinical benefit, but real-world patterns of initiation, interruption, and discontinuation in US oncology practices had not been characterized.

Solution

Target RWE researchers analyzed administrative claims data to characterize initiation and interruption patterns of IV bisphosphonate therapy in multiple myeloma patients, identifying patient- and practice-level predictors of guideline-concordant therapy management.

Impact

Characterizing real-world IV bisphosphonate utilization patterns in multiple myeloma provides evidence of treatment gaps that oncology drug development partners can use to design supportive care studies and clinical decision support interventions.